April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Effect of Intrastromal Bevacizumab Injection on Corneal Neovascularization: An in vivo Evaluation
Author Affiliations & Notes
  • M. Fossarello
    Ophthalmology, University of Cagliari, Cagliari, Italy
  • E. Peiretti
    Ophthalmology, University of Cagliari, Cagliari, Italy
  • M. Vinci
    Ophthalmology, University of Cagliari, Cagliari, Italy
  • F. Orru`
    Ophthalmology, University of Cagliari, Cagliari, Italy
  • Footnotes
    Commercial Relationships  M. Fossarello, None; E. Peiretti, None; M. Vinci, None; F. Orru`, None.
  • Footnotes
    Support  UNICA Ricerca Locale (ex 60%)
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5703. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Fossarello, E. Peiretti, M. Vinci, F. Orru`; Effect of Intrastromal Bevacizumab Injection on Corneal Neovascularization: An in vivo Evaluation. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5703.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : to determine the effect of intrastromal bevacizumab injections on corneal neovessels (CNV).

Methods: : ten eyes were studied in 10 patients with an average age of 64.5 +/- 16.2 years. Patients underwent peripheral corneal intrastromal bevacizumab injections using a 30 G needle at a concentration of 5 mg/0.2 mL. .Intraocular pressure, best-corrected visual acuity, neovascular net extent, anterior segment photography, corneal fluorescein angiography, pachymetry, corneal sensitivity and specular microscopy were recorded preoperatively and postoperatively.

Results: : the minimum follow-up period was 6 months. CNVs started to regress within the first 4 days after the injection, and regressed completely by the end of the fourth week in four patients, and regressed partially in six patients. CNV regressed completely after 3 monthly injections in four out of these six patients. . In two patient regression of CNV was not complete. No systemic or local side effects were observed.

Conclusions: : 1 to 3 corneal intrastromal 5 mg/ 0,2 mL bevacizumab injections may be effective in reducing corneal neovascularization in humans without observed side effects.

Keywords: cornea: clinical science • cornea: stroma and keratocytes • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×